^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
IDH wild-type
i
Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble, IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
2d
Phase I Trial of pH Resections of GBM at VA (clinicaltrials.gov)
P1, N=12, Not yet recruiting, VA Office of Research and Development | Trial completion date: Feb 2031 --> Jul 2031 | Initiation date: Feb 2026 --> Jul 2026 | Trial primary completion date: Feb 2031 --> Jul 2031
Trial completion date • Trial initiation date • Trial primary completion date
|
RAS wild-type • IDH wild-type
2d
SHINE-GLIO: Mental Health and Suicidality in Glioblastoma Patients in Germany (clinicaltrials.gov)
P=N/A, N=176, Not yet recruiting, University Hospital, Essen
New trial
|
IDH wild-type
3d
Redundancy in Growth Factor Receptor Signaling in Adult Astrocytoma Resistance to Small-Molecule Tyrosine Kinase Inhibitors. (PubMed, Int J Mol Sci)
The molecular processes driving this resistance are complex and not yet fully understood. In this review, we briefly present the growth factor receptors (GFRs) and their signaling pathways in adult astrocytomas and discuss the known mechanisms of resistance to small-molecule tyrosine kinase inhibitors.
Review • Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
4d
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)
P1, N=56, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting
Enrollment closed
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • IDH wild-type
|
WSD0922
4d
IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis. (PubMed, bioRxiv)
In addition, treatments with the IDH-mutant inhibitors vorasidenib and ivosidenib further sensitize the cells to ferroptosis. Furthermore, dietary cysteine-methionine deprivation alone or in combination with convection-enhanced delivery of RSL3 or ivosidenib in vivo significantly prolongs survival of IDH1-mutant tumor-bearing mice. Our findings suggest that targeting cysteine and methionine metabolism in combination with IDH-mutant inhibition provides promising therapeutic strategies for IDH1-mutant gliomas.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH wild-type
|
Tibsovo (ivosidenib) • Voranigo (vorasidenib) • RSL3
4d
The atypical kinase right open reading frame kinase 1 suppresses glioma cell growth through mammalian target of rapamycin inhibition and apoptotic signaling activation. (PubMed, Transl Cancer Res)
RIOK1 expression is lower in glioma tissues than in non-tumor brain tissues, and is particularly lower in IDH wild-type gliomas. RIOK1 functions as a suppressor of glioma cell survival and proliferation, possibly through mTOR pathway inhibition and apoptotic pathway activation.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
IDH wild-type
5d
Defying the Odds in Recurrent Glioblastoma: Complete Response following Salvage Therapy with Bevacizumab and Irinotecan - A Case Report. (PubMed, Case Rep Oncol)
In this discourse, we delineate the case of a 42-year-old male patient diagnosed with IDH-wild-type, MGMT-unmethylated, TERT promoter-mutated, and EGFR-amplified GBM, who manifested an early recurrence during adjuvant temozolomide therapy. Our findings, contextualized within contemporary evidence on re-irradiation (stereotactic radiosurgery/fractionated stereotactic radiation therapy) and combinatorial strategies (BEV with lomustine or irinotecan), underscore the need for further empirical investigation to optimize treatment sequencing in r-GBM. This case emphasizes the necessity for individualized multimodal approaches to improve outcomes in this refractory patient population.
Journal
|
EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase)
|
EGFR mutation • EGFR amplification • IDH wild-type
|
Avastin (bevacizumab) • temozolomide • irinotecan • lomustine
6d
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma (clinicaltrials.gov)
P2, N=57, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGFR (Fibroblast Growth Factor Receptor) • CDK12 (Cyclin dependent kinase 12) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CHEK2 (Checkpoint kinase 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)
|
CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
6d
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. (PubMed, Neurooncol Adv)
Brigimadlin is highly effective in MDM2-amplified GBM when adequate drug levels are achieved in tumor tissue. MDM2 amplification impacts both treatment efficacy and intratumoral drug accumulation.
PK/PD data • Journal
|
MDM2 (E3 ubiquitin protein ligase) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • RAG1 (Recombination Activating 1)
|
TP53 wild-type • IDH wild-type
|
brigimadlin (BI 907828)
9d
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma (clinicaltrials.gov)
P1/2, N=54, Not yet recruiting, Washington University School of Medicine
New P1/2 trial
|
IDH wild-type
|
tovecimig (CTX-009)
10d
MIF-mediated reprogramming of myeloid lineage within the glioma tumor microenvironment impacts the efficacy of immune stimulatory gene therapy. (PubMed, bioRxiv)
These findings highlight the therapeutic potential of targeting the MIF-CD74 pathway and underscore the importance of integrating immunomodulatory strategies for the treatment of glioma. Mutant IDH1 gliomas exhibit fewer Mo-TAMs and increased Mg-TAMsMutant IDH1 gliomas have less MIF expression via epigenetic reprogramming.Mesenchymal wtIDH1 glioma cells are main source of MIF.MIF inhibition plus immune stimulatory gene therapy extends survival wtIDH1 glioma.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CD74 (CD74 Molecule) • MIF (Macrophage Migration Inhibitory Factor)
|
IDH1 mutation • IDH wild-type
11d
CAN-201 NDG: Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma (clinicaltrials.gov)
P1/2, N=18, Active, not recruiting, Cantex Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
S100A9 (S100 Calcium Binding Protein A9)
|
IDH wild-type
|
temozolomide • azeliragon (TTP488)
Share via
